Taro Pharmaceutical Industries Ltd.
TARO · NYSE
3/31/2024 | 3/31/2023 | 3/31/2022 | 3/31/2021 | |
|---|---|---|---|---|
| Revenue | $1 | $1 | $1 | $1 |
| % Growth | 9.8% | 2.1% | 2.3% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 48.5% | 46.8% | 52.2% | 54% |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $0 | $0 | $0 | $0 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Income | $0 | $0 | $0 | $1 |
| % Margin | 3.4% | 3.1% | 32.8% | 128.3% |
| Other Income/Exp. Net | $0 | $0 | -$0 | -$1 |
| Pre-Tax Income | $0 | $0 | $0 | -$0 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | $0 | $0 | $0 | -$0 |
| % Margin | 8.6% | 4.4% | 10.4% | -73% |
| EPS | 1.43 | 0.68 | 1.55 | -10.49 |
| % Growth | 110.3% | -56.1% | 114.8% | – |
| EPS Diluted | 1.43 | 0.68 | 1.55 | -10.49 |
| Weighted Avg Shares Out | 0 | 0 | 0 | 0 |
| Weighted Avg Shares Out Dil | 0 | 0 | 0 | 0 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | $0 | $0 | $0 | -$0 |
| % Margin | 6.1% | 9.7% | 29.4% | -75.4% |